Marksans Pharma Limited (MARKSANS) — base & breakout chart
Healthcare · PharmaceuticalsStock page
Where it stands
- Stage
- Fresh breakouts
- Pivot
- ₹345.50
- Price
- ₹331.55
- RS
- 91
4.0% to go±25%
Sessions since 3Turnover ₹54.4 Cras of 28 Sept 2026
Trend
- Above 50-day: yes
- Above 150-day: yes
- Above 200-day: yes
- 150-day over 200-day: yes
- Trend template met: yes
Bulk/block deals: 1 buy / 1 sellInsiders net sellers (0 buy / 2 sell)
Price chart with bases
6th base on record. The latest cleared its ₹345.50 pivot on 23 Sept 2026.
Price chart of MARKSANS, 493 daily bars from 2024-09-30 to 2026-09-28, with 1 bases shaded. Every base is listed in the table below.
Base history
Every base the detector recorded for this stock, newest first. Select one to highlight it on the chart.
| Base | Formed | Base age | Depth | Pivot | Contractions | Squats / pokes | Outcome |
|---|---|---|---|---|---|---|---|
| 17 Aug 2026 – 22 Sept 2026 | 5w | 12.9% | ₹345.50 | 1(last 14.0%) | 0 / 1 | Broke out23 Sept 2026 on 1.2× vol |
Showing the latest of 6 bases on record. The 5 earlier ones are drawn on the chart and listed here with Pro.
You were looking for stocks building a base.See every setup
What this chart shows
Marksans Pharma Limited (MARKSANS) closed above the ceiling of its latest base on 23 Sep 2026 (3 trading sessions ago). That base ran from 17 Aug 2026 to 22 Sep 2026, about 5 weeks. Its ceiling — the highest price inside the base, which traders call the pivot — was ₹345.50. On the breakout day it closed at ₹347.60, on trading volume 1.2 times its average daily volume during the base. The last close on 28 Sep 2026 was ₹331.55, 4.0% below the ceiling. So although it broke out, it has since closed back under the level it cleared. From its highest point to its lowest, the base is 12.9% deep. Inside it there has been a single pullback so far. In our four-stage lifecycle it is currently "fresh breakout": closed above its ceiling within the last five sessions.
Its relative strength reading is 91 out of 99. That means its price over the past year has done better than about 91% of the 940 stocks we rank. It is a comparison with other stocks, not a forecast. Among the 71 Pharmaceuticals & Biotechnology stocks we track, it ranks 9 of 71 by that reading. The last close is above its 50-day, 150-day and 200-day averages — the average closing price over the last 50, 150 and 200 trading sessions, which people use to judge the longer trend. The 150-day average is itself above the 200-day average.
Since our base records begin (April 2024), we have found six bases in MARKSANS. All six broke out above their ceilings. Today's price is above the breakout-day close of 4 of those 6 breakouts.
How to read this page: a base is a stretch of weeks or months in which a stock stops trending and moves sideways within a range. The top of that range is its ceiling, which traders call the pivot; a close above it is what we count as a breakout. Relative strength compares a stock's price performance over the past year with every other stock we track, on a scale of 1 to 99. All of this describes what the price has already done. It is not a recommendation to buy or sell, and it does not predict what the price will do next. Our price history begins in 2020, so any "high" on this page means the highest price since 2020.
How to read it
- Shaded box — a base: the stretch where the stock stopped trending and traded sideways, from its high (the pivot) down to its lowest low.
- Line at the top of the box — the pivot, the price a close has to clear for the base to resolve upward. It runs on to the breakout, or to today for a base still forming.
- Arrow under a candle — the breakout day, with that day's volume as a multiple of the base's own average.
- P and S — a failed poke (traded above the pivot but closed back under it) and a squat (closed just under the pivot on light volume).
Prices are adjusted for splits and bonuses. Our price history starts in 2020, so any high mentioned here is a high since 2020, not an all-time high. Base detection describes past price and volume; it is for research and education, is not investment advice, and no pattern predicts future returns.